Daily Ards Research Analysis
Today’s top studies span translational, diagnostic, and clinical management advances relevant to acute respiratory distress syndrome (ARDS) and neonatal respiratory care: a scalable platform for recombinant plasma gelsolin production, spectroscopy-driven detection strategies for the hyperinflammation marker hepcidin-25, and practical guidelines for implementing non-invasive NAVA in neonates.
Summary
Today’s top studies span translational, diagnostic, and clinical management advances relevant to acute respiratory distress syndrome (ARDS) and neonatal respiratory care: a scalable platform for recombinant plasma gelsolin production, spectroscopy-driven detection strategies for the hyperinflammation marker hepcidin-25, and practical guidelines for implementing non-invasive NAVA in neonates.
Research Themes
- Enabling biomanufacturing for ARDS/sepsis therapeutics (plasma gelsolin)
- Point-of-care biomarker detection using FTIR/Raman (hepcidin-25)
- Neonatal synchronized non-invasive ventilation (NIV-NAVA) best practices
Selected Articles
1. Scalable production of functional recombinant human plasma gelsolin in Escherichia coli for therapeutic and diagnostic applications.
A GST-TEV fusion strategy with high-density fed-batch E. coli fermentation yielded 5.0 g/L soluble protein and 2.1 g/L tag-free, >95% purity recombinant gelsolin. Structural (CD, terminal sequencing) and functional (Ca2+-dependent actin binding/severing) validations showed native-like properties. This cost-effective platform enables preclinical and diagnostic development for ARDS/sepsis-related applications.
Impact: Delivers one of the highest reported yields of functional human plasma gelsolin with orthogonal validation, directly enabling translational studies and potential therapeutic manufacturing.
Clinical Implications: By ensuring scalable access to bioactive plasma gelsolin, this work supports future trials testing gelsolin supplementation in sepsis or ARDS and facilitates standardized assays for gelsolin as a biomarker.
Key Findings
- High-density fed-batch E. coli production achieved 5.0 g/L soluble protein and 2.1 g/L tag-free rGelsolin with >95% purity.
- CD spectroscopy showed native-like secondary structure and thermal stability (Tm ~59 °C); N- and C-terminal sequencing confirmed correct processing.
- Functional assays demonstrated Ca2+-dependent actin binding and severing comparable to native plasma gelsolin.
Methodological Strengths
- Orthogonal structural and functional validation (CD, terminal sequencing, actin dynamics assays).
- Scalable and reproducible bioprocess (GST-TEV strategy with fed-batch fermentation and streamlined purification).
Limitations
- No in vivo efficacy or safety data; translational performance remains untested.
- Immunogenicity, pharmacokinetics, and GMP-scale manufacturing were not evaluated.
Future Directions: Test rGelsolin in preclinical ARDS/sepsis models, evaluate PK/PD and immunogenicity, and develop GMP workflows and diagnostic assay standardization.
Human plasma gelsolin (pGSN) is an 83 kDa actin-binding protein involved in cytoskeletal remodeling, inflammation, and host defense. Its clinical relevance as a biomarker and potential therapeutic agent, particularly in conditions like sepsis, acute respiratory distress syndrome (ARDS), and cystic fibrosis, has driven interest in scalable recombinant expression. However, high-yield production of functionally active gelsolin is hindered by its complex structure and folding requirements. To address this, we developed a scal
2. Vibrational and electronic spectral analysis of Hepcidin-25 hormone: Perspectives for hyperinflammation diagnosis.
Experimental FTIR/Raman spectra combined with DFT and MD enabled full band assignments for hepcidin-25 and determination of detection limits. Findings support serum-based detection via FTIR or Raman for rapid hyperinflammation assessment, while saliva requires ~1000× sensitivity improvement.
Impact: Provides physics-based spectral fingerprints and detection limits that can directly inform point-of-care device design for rapid hepcidin testing in ARDS, sepsis, and COVID-19.
Clinical Implications: If validated in clinical samples, FTIR/Raman-based hepcidin testing could enable rapid triage and risk stratification for hyperinflammatory states, complementing existing laboratory assays.
Key Findings
- Comprehensive FTIR and Raman spectra with DFT/MD simulations enabled assignment of all observed bands in the fingerprint region.
- Detection limits indicate feasibility of serum-based hepcidin-25 measurement using FTIR or Raman.
- Saliva-based detection currently requires approximately 1000-fold sensitivity enhancement.
Methodological Strengths
- Integration of experimental spectroscopy with ab initio DFT and MD for cross-validation.
- Quantitative determination of detection limits across techniques (FTIR and Raman).
Limitations
- Clinical validation in real patient biofluids is not reported.
- Potential matrix effects and interferences in complex serum/saliva environments are not fully addressed.
Future Directions: Validate in clinical cohorts, assess matrix effects, and engineer plasmonic or signal-enhanced platforms to achieve saliva-level sensitivity.
The hormone hepcidin-25 is a molecule that regulates iron metabolism. It is present in biofluids and it is a hyperinflammation marker for critical pathological states such as anaphylaxis, acute respiratory distress syndrome, autoimmune diseases, sepsis, and COVID-19, among others. Its fast detection and quantification are of key importance in health strategies for fatality prediction. Vibrational spectroscopy techniques such as Fourier-transform infrared (FTIR) and Raman spectroscopies are potential
3. Optimizing synchronized non-invasive support: Clinical management guidelines for non-invasive neurally adjusted ventilatory assist.
The guideline outlines practical setup and management of NIV-NAVA in neonates, emphasizing improved patient-ventilator synchrony, reliable monitoring via Edi, and self-regulating support. It summarizes evidence and experience where NIV-NAVA helped prevent intubation and facilitated early extubation, and contrasts key differences from conventional NIV.
Impact: Provides implementable, physiology-based guidance for synchronized non-invasive support in neonates, potentially improving outcomes and reducing invasive ventilation.
Clinical Implications: Adopting NIV-NAVA with appropriate setup and monitoring could enhance synchrony, reduce work of breathing, and decrease intubation rates in neonatal units, provided teams are trained on Edi-based management.
Key Findings
- NIV-NAVA uses diaphragm electrical activity (Edi) to maintain synchrony despite leaks, enabling tailored non-invasive support.
- Evidence and clinical experience indicate roles in preventing intubation and facilitating early extubation in neonates.
- Practical setup and management differ from conventional NIV, requiring specific understanding of NAVA parameters and Edi monitoring.
Methodological Strengths
- Clinically focused synthesis of multiple studies and bedside experience.
- Clear operational guidance for setup, titration, and monitoring.
Limitations
- Narrative guideline without systematic review methodology; limited high-quality RCT evidence.
- Generalizability may vary across units due to equipment availability and team expertise.
Future Directions: Prospective comparative studies and RCTs to quantify benefits versus conventional NIV, and training frameworks to standardize Edi-based management.
Neurally Adjusted Ventilatory Assist (NAVA) is an innovative ventilation mode that empowers patients to control both the timing and level of ventilatory support. By utilizing the electrical activity of the diaphragm (Edi) as the control signal, NAVA enables synchronized non-invasive ventilation (NIV-NAVA) even in the presence of leaks, while also providing continuous monitoring of the patient's respiratory pattern and drive. NIV-NAVA offers several advantages compared to conventional non-invasive venti